The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.
Pirfenidone Prevents the Development of a Vulnerable Substrate for Atrial Fibrillation in a Canine Model of Heart Failure
Open accessAbstract
Background— Atrial fibrosis is an important substrate in atrial fibrillation (AF), particularly in the setting of structural heart disease. In a canine model, congestive heart failure (CHF) produces significant atrial fibrosis and the substrate for sustained AF. This atrial remodeling is a potential therapeutic target. The objective of the present study is to evaluate the effects of the antifibrotic drug pirfenidone (PFD) on arrhythmogenic atrial remodeling in a canine CHF model. Methods and Results— We studied 15 canines, divided equally into 3 groups: control, CHF canines not treated with PFD, and CHF canines treated with PFD. CHF was induced by ventricular tachypacing (220 bpm for 3 weeks), and oral PFD was administered for the 3-week pacing period. We performed electrophysiology and AF vulnerability studies, atrial fibrosis measurements, and atrial cytokine expression studies. Only canines in the untreated CHF group developed sustained AF (>30 minutes, 4 of 5 canines; P <0.05). Treatment of CHF canines with PFD resulted in an attenuation of arrhythmogenic left atrial remodeling, with a significant reduction in left atrial conduction heterogeneity index (median [25% to 75% interquartile range] 4.96 [3.53 to 5.64] versus 2.52 [2.11 to 2.82], P <0.01; pacing cycle length 300 ms), left atrial fibrosis (16.0% [13.0% to 17.5%] versus 8.7% [5.7% to 10.6%], P <0.01), and AF duration (1800 [1020 to 1800] seconds versus 6 [5 to 22] seconds, P <0.01). Immunoblotting studies demonstrated the drug’s effects on multiple cytokines, including a reduction in transforming growth factor-β1 expression. Conclusions— Treatment of CHF canines with PFD results in significantly reduced arrhythmogenic atrial remodeling and AF vulnerability. Pharmacological therapy targeted at the fibrotic substrate itself may play an important role in the management of AF.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
ANNE, W., WILLEMS, R., ROSKAMS, T., SERGEANT, P., HERIJGERS, P., HOLEMANS, P., ECTOR, H., & HEIDBUCHEL, H. (2005) · Cardiovascular Research · doi:10.1016/j.cardiores.2005.04.016 · Cited by 210
Cited by
Pathophysiological mechanisms of atrial fibrillation: a translational appraisal
Schotten, U., Verheule, S., Kirchhof, P., & Goette, A. (2011) · Physiological Reviews · doi:10.1152/physrev.00031.2009 · Cited by 1,273
“(523), pirfenidone (318), polyunsaturated 3 fatty acids”
BackgroundAtrial Fibrosis: Mechanisms and Clinical Relevance in Atrial Fibrillation
Burstein, B., & Nattel, S. (2008) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2007.09.064 · Cited by 1,242
Atrial Remodeling and Atrial Fibrillation: Mechanisms and Implications
Nattel, S., Burstein, B., & Dobrev, D. (2008) · Circulation: Arrhythmia and Electrophysiology · doi:10.1161/circep.107.754564 · Cited by 1,124
Atrial Fibrillation and Heart Failure: Treatment Considerations for a Dual Epidemic
Anter, E., Jessup, M., & Callans, D. J. (2009) · Circulation · doi:10.1161/circulationaha.108.821306 · Cited by 678
Structural and Functional Remodeling of the Left Atrium
Casaclang-Verzosa, G., Gersh, B. J., & Tsang, T. S. M. (2008) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2007.09.026 · Cited by 529
Antifibrotic activities of pirfenidone in animal models
Schaefer, C. J., Ruhrmund, D. W., Pan, L., Seiwert, S. D., & Kossen, K. (2011) · European Respiratory Review · doi:10.1183/09059180.00001111 · Cited by 454
Left Atrial Reverse Remodeling
Thomas, L., & Abhayaratna, W. P. (2017) · JACC: Cardiovascular Imaging · doi:10.1016/j.jcmg.2016.11.003 · Cited by 385
Yue, L., Xie, J., & Nattel, S. (2011) · Cardiovascular Research · doi:10.1093/cvr/cvq329 · Cited by 366
Heart failure with preserved ejection fraction: from mechanisms to therapies
Lam, C. S. P., Voors, A. A., de Boer, R. A., Solomon, S. D., & van Veldhuisen, D. J. (2018) · European Heart Journal · doi:10.1093/eurheartj/ehy301 · Cited by 355
Atrial fibrosis and the mechanisms of atrial fibrillation
Everett, T. H., & Olgin, J. E. (2007) · Heart Rhythm · doi:10.1016/j.hrthm.2006.12.040 · Cited by 338
Self-citationTargeting the cancer-associated fibroblasts as a treatment in triple-negative breast cancer
Takai, K., Le, A., Weaver, V. M., & Werb, Z. (2016) · Oncotarget · doi:10.18632/oncotarget.12658 · Cited by 207
Artemisinin and artemisinin derivatives as anti-fibrotic therapeutics
Dolivo, D., Weathers, P., & Dominko, T. (2021) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2020.09.001 · Cited by 132
Pirfenidone for idiopathic pulmonary fibrosis and beyond
Aimo, A., Spitaleri, G., Nieri, D., Tavanti, L. M., Meschi, C., Panichella, G., Lupón, J., Pistelli, F., Carrozzi, L., Bayes-Genis, A., et al. (2022) · Cardiac Failure Review · doi:10.15420/cfr.2021.30 · Cited by 88
Metadata
- Authors
- Lee, K. W., Everett, T. H., Rahmutula, D., Guerra, J. M., Wilson, E., Ding, C., & Olgin, J. E.
- Venue
- Circulation
- Published
- 2006-10-17
- Volume
- 114
- Issue
- 16
- Pages
- 1703-1712
- ISSN
- 0009-7322 (ISSN-L)
- 1524-4539
- OpenAlex
- W2090876614
- Cited by
- 224
- References
- 1
- FWCI
- 7.22
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.